Testosterone Enanthate: Indications, Dosing, Half-Life, and Storage

Three questions account for most of what our pharmacy team gets asked about testosterone enanthate. How often does the injection get repeated. How long does it actually stay active. And can the vial sit in a bathroom cabinet for a month without going bad.

The answers are in the approved labeling. They tend to get garbled between the label and the search results, and the half-life number is the worst offender.

One note first. You will also see this written as testosterone ethanate. Same ester, misspelled. No second drug hides behind the alternate spelling.

What Is Testosterone Enanthate?

Structurally it is testosterone carrying an enanthate ester, a seven-carbon heptanoate chain, at the 17-beta hydroxyl group. The ester does no therapeutic work itself. Its whole job is slowing the exit from the injection site, which turns a hormone with a very short circulating life into something dosed every few weeks rather than every day.

Two facts about it shape everything downstream. It is an androgen and an anabolic steroid by pharmacologic class. And it is a Schedule III controlled substance under the Controlled Substances Act, which attaches to the molecule no matter who prepares it or why. A prescription from a licensed prescriber is required, always.

In the United States, the manufactured injection comes as a 200 mg/mL oil solution in a 5 mL multiple-dose vial, per the FDA-approved product labeling published on DailyMed. The UK presentation is 250 mg/mL. That single difference is why a dosing figure copied off a British forum rarely matches what a US patient is holding.

Compounded testosterone preparations are a different category. They are made under one patient’s prescription, when the commercial product is unavailable or unsuitable for that person, and they are not reviewed by the FDA for safety or effectiveness. The prescriber makes that call, not the pharmacy and not the patient.

How Does the Enanthate Ester Work in the Body?

The oil depot is the whole mechanism. Testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase, and the labeling names that as the reason the drug can be given at intervals of two to four weeks. Enzymes cleave the ester, testosterone enters circulation, and it behaves the way endogenous testosterone behaves.

Which is to say androgens govern development of the male reproductive tissues and maintenance of secondary sex characteristics. They also affect retention of nitrogen, sodium, potassium and phosphorus, along with urinary calcium excretion.

The attribution matters here. Those effects belong to the androgen class and to the testosterone molecule. Not to any formulation of it, compounded or manufactured.

Half-Life, and Why the Published Number Varies

Here is where the internet and the labeling part ways.

The MHRA-approved Summary of Product Characteristics for testosterone enantate 250 mg/mL puts half-life in blood at 2 to 3 days in healthy male volunteers. The US label offers no ester half-life whatsoever. What it does say is that free testosterone concentration determines the half-life of testosterone itself, which the literature reports anywhere from 10 to 100 minutes.

Those are two different measurements wearing the same word. The 2 to 3 days describes how long the esterified drug hangs around. The minutes describe unbound testosterone after release.

Figures above 4 days are everywhere online and appear in neither regulatory label. I realize splitting hairs over a day or two sounds academic. It stops being academic when someone told the drug lasts a week decides a missed injection is not worth a call.

How Is Testosterone Enanthate Dosed and Administered?

One boundary before the numbers. Everything here describes testosterone enanthate as prescribed for the indications in its approved labeling, and physique or athletic performance is not among them. Within those indications the labeling gives ranges rather than one figure, and the prescriber sets the dose per patient.

• For replacement therapy in males with primary hypogonadism or hypogonadotropic hypogonadism, and for eunuchism, the range is 50 to 400 mg every 2 to 4 weeks.
• Delayed puberty is dosed lower and, importantly, for a bounded stretch of time. 50 to 200 mg every 2 to 4 weeks, over something like 4 to 6 months.
• The third labeled use surprises people who assume this is a men’s-health-only drug. Palliation of inoperable mammary cancer in women, at 200 to 400 mg every 2 to 4 weeks.

On the male indications, the labeling covers replacement where endogenous testosterone is deficient or absent. Primary hypogonadism means testicular failure, from cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy. Hypogonadotropic hypogonadism means gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma or radiation.

And then there is the limit that almost never travels alongside the dosing figures. Safety and efficacy in men with age-related hypogonadism have not been established. That is the label’s own wording, and it is the sentence I would want in front of me when a patient arrives convinced testosterone is a general-purpose remedy for getting older. Broader context on how prescribers approach this sits in our hormone replacement therapy compounding services.

Intramuscular Injection Technique

The conventional oil solution is an intramuscular product. Slow, deep, into the gluteal muscle, with the usual precautions for intramuscular administration and care to avoid intravascular injection. The labeling states that injections are well tolerated when properly given. That qualifier is doing real work.

Can Testosterone Enanthate Be Given Subcutaneously?

Yes, in the product built for it. Not in the one that is not.

There is an FDA-approved autoinjector for subcutaneous use, supplied as a single-dose autoinjector in three strengths, 50 mg, 75 mg and 100 mg per 0.5 mL. Starting dose is 75 mg once a week, subcutaneously, in the abdominal region. That product’s labeling restricts injection to the abdomen and nowhere else.

The multiple-dose vial is a separate product with its own approved route, concentration and schedule. It is labeled intramuscular at 200 mg/mL. Whether subcutaneous administration suits a patient is a prescriber’s decision, not something anyone resolves by changing their own technique.

How Should Testosterone Enanthate Be Stored?

This is the one we field most, and the answer is more specific than “somewhere sensible.”

Store at 20 to 25 degrees C (68 to 77 degrees F). That is USP Controlled Room Temperature. The subcutaneous autoinjector carries the same window and permits excursions to 15 to 30 degrees C (59 to 86 degrees F). Room temperature products, both of them.

Does It Need to Be Refrigerated?

No, and refrigerating it introduces a problem that does not otherwise exist. Cold makes the drug crystallize out of the oil.

The fix is in the labeling and it is refreshingly low-tech. Warming and rotating the vial between the palms of the hands will redissolve crystals that formed during storage at low temperatures.

So crystals or cloudiness after a vial has been somewhere cold are not proof the product is finished. Warm it. Rotate it. Look again. A vial that stays cloudy after all that is worth a phone call to whoever dispensed it.

I know this reads like housekeeping trivia. It is not trivia to the person holding a vial that spent February in an unheated room, trying to decide whether to bin a product that may be perfectly fine.

Storage Conditions to Avoid

• Bathroom cabinets and windowsills, where humidity and direct sun quietly walk the vial out of its labeled range.
• Cars. A glove compartment in July clears the upper limit fast, and nobody thinks of the car as storage.
• The fridge, for the crystallization reason above, and the freezer for the same reason plus worse.
• Anywhere the temperature is simply unknown, since the labeled window is the only condition the stability data actually supports.

Beyond-Use Dating After the Vial Is Opened

Two dates govern a multiple-dose vial, and patients are usually only aware of one.

The manufacturer’s expiration date covers the container while it is sealed. The moment the closure is punctured, a beyond-use date takes over instead, and it is generally shorter than the printed expiration.

Beyond-use dating for punctured multiple-dose containers follows USP standards for sterile preparations, and the dispensing pharmacy assigns the applicable date. Read the dispensing label rather than the manufacturer’s expiration alone. When the two disagree, ask, because the shorter one is the one that matters. We document the applicable beyond-use date on every sterile preparation we dispense, and our quality and compliance standards cover the conditions behind it.

Testosterone Enanthate vs. Cypionate, and How the Esters Differ

No question about this ester comes up more, and the answer disappoints people who arrive wanting a winner. The two are close. Both are long-acting oil-based testosterone esters, injected on a similar schedule, differing in a chain length that is a single carbon apart.

That extra carbon makes cypionate marginally more lipophilic, which is the entire basis for the claim that it releases more slowly. The chemistry is real. Inside labeled dosing intervals the two get treated identically, and the practical gap is smaller than the argument it generates.

Neither ester is better than the other, and this page is not going to pretend otherwise. The choice belongs to the prescriber, weighing the individual patient, what is actually available, and how that patient responds over time. For the shorter-acting end of the range, see our overview of testosterone cypionate and testosterone propionate, and the compounded testosterone therapy guide walks through how these decisions get made.

What Side Effects and Monitoring Does the Ester Require?

The labeling catalogs adverse reactions across most body systems. Hirsutism, male pattern baldness and acne. Myocardial infarction and stroke. Retention of sodium, chloride, water, potassium, calcium and inorganic phosphates. Nausea, cholestatic jaundice and altered liver function tests, with hepatocellular neoplasms and peliosis hepatis reported rarely. Suppression of clotting factors II, V, VII and X, along with polycythemia.

Against that, the labeling names specific monitoring that a prescriber will generally order.

• Hemoglobin and hematocrit, checked periodically, because polycythemia is the one that shows up in patients on high androgen doses.
• Bone age X-rays every six months in pre-pubertal males. The concern is skeletal maturation and what androgen therapy does to the epiphyseal centers.
• Serum and urine calcium, determined frequently, in women receiving androgen therapy for disseminated breast carcinoma.

The interaction list matters as much as the adverse-event list, and it gets less attention. Androgens may reduce oral anticoagulant requirements, so anyone on warfarin or a similar agent needs close monitoring when androgen therapy starts or stops. In diabetic patients, androgens may lower blood glucose and insulin requirements. Alongside ACTH or corticosteroids, the tendency toward edema goes up. Serum oxyphenbutazone levels may rise.

None of which replaces a prescriber’s read on a specific patient. It is what the labeling tells clinicians to keep an eye on.

Questions Providers and Patients Ask Most